Supporting Your Immune Response
The probiotic strain AB21 is the first clinically validated for the treatment of Covid-19.
A study including 300 non-hospitalized adult participants with PCR-confirmed COVID-19 and mild symptoms:
Remission rate, as measured by both the absence of COVID-19 symptoms and a negative RT-PCR test.
Reduction in the number of symptomatic patients with COVID-19.
Reduction in the duration of specific symptoms.
Reduced viral load in nasopharyngeal swabs.
Increased specific IgG and IgM levels against SARS-CoV-2.
The study is currently awaiting peer review.
The Gut-Lung Axis
Our lungs have their own microbiota, and these microbes can communicate with the microbes in our gut. This is known as the gut-lung axis. This communication is mediated in part by microbial metabolites such as short chain fatty acids (SCFAs), tryptophan metabolites, toll-like receptor (TLR) or nucleotide-binding oligomerization domain (NOD) ligands.
Research has suggested that this gut-lung axis may affect how respiratory illnesses and diseases progress and may influence how severally you suffer. Additionally, probiotics may have a role in the prevention or reduction of duration in respiratory tract infections (RTIs). Evidence has suggested that administration of certain bifidobacteria or lactobacilli has shown to be beneficial on respiratory virus clearance from the respiratory tract.
A paper published this year by Yun Kit Yeoh et al., showed that there was a link between gut microbiota composition and disease severity and dysfunctional immune response in patients with COVID-19. It was demonstrated that patients who suffered more severely from COVID-19 were depleted in gut bacteria with known immunomodulatory potential, such as Faecalibacterium prausnitzii, Eubacterium rectale and several bifidobacterial species.
The paper then suggested increasing these beneficial gut species depleted in COVID-19 could serve as a novel avenue to mitigate severe disease.
What was the study design?
The study was a randomised controlled trial.
How many participants were included in the study?
300 adults aged 18-60 were recruited.
What were the study inclusions?
Male and female, aged 18-60. Positive for SARS-Cov-2 (confirmed by a RT-PCR test). Symptomatic for SARS-CoV-2 but not hospitiliasied (SpO2 ≥ 90%).
Who were the lead researchers?
The research leads were J. Espadaler-Mazo PhD, AB-BIOTICS R&D Department (Kaneka Group) and P. Gonzalez-Castrellon MD, Hospital General Manuel Gea Gonzalez, Mexico City.
Where was the study carried out?
Hospital General Manuel Gea González, Mexico City (Mexico).
Where there any differences between patients?
The effects were significant after adjusting for potential influencing factors including age, sex, SpO2 , BMI, viral load.
AB21 formula is designed with the aim to bring a good anti-inflammatory
activity, improve immune response (anti-viral effect and stimulation of Ig’s
production) and to enhance intestinal barrier.
2 billion friendly bacteria
4 live strains
Lactobacillus plantarum KABP™ 033
Lactobacillus plantarum KABP™ 022
Lactobacillus plantarum KABP™ 023
Pediococcus acidilactici KABP™ 021
Added vitamin D
What probiotic species are found in AB21?
Pediococcus acidilactici CECT 7483 (KABPTM 021), Lactobacillus plantarum CECT 7484 (KABPTM 022), Lactobacillus plantarum CECT 7485 (KABPTM 023), Lactobacillus plantarum CECT 30292 (KABPTM 033).
What is the CFU?
Each capsule provides 2 billion bacteria per capsule.
What is the mechanism of actions of the strains?
Anti-permeability (polyphosphate granules)
Anti-inflammatory activity (acetate, Ach)
Will AB21 be prescribed by a doctor?
No, it is a food supplement, not a drug. But many doctors, once comfortable with the data, might want to recommend their patients try taking Probio7 AB21 as soon as they experience COVID-19 symptoms. People might also want to use it from when they have their first vaccination. However, these effects are still to be clinically confirmed by further research.